首页 > 最新文献

Stroke and Vascular Neurology最新文献

英文 中文
Antithrombotic therapy in patients with COVID-19: indications, pharmacotherapy and controversy. 新冠肺炎患者的抗凝治疗:适应症、药物治疗和争议。
IF 5.9 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2023-08-01 Epub Date: 2023-02-16 DOI: 10.1136/svn-2023-002321
David Wang, Christopher Leo, Liping Liu, Li Huang, Lisa Huang, Yun Lu
Department of Neurology, Petznick Stroke Center, Barrow Neurological Institute, Phoenix, Arizona, USA Department of Medicine/ Division of General Internal Medicine/Hospital Medicine, Duke University, Durham, North Carolina, USA Neurosurgical Intensive Care Unit (NICU), Beijing Tiantan Hospital, Capital Medical University, Beijing, China China National Clinical Research Center for Neurological Diseases, Beijing, China Doctors Medical Center, Modesto, California, USA Chesapeake Regional Medical Center, Chesapeake, Virginia, USA Hennepin Healthcare System and the University of Minnesota, Minneapolis, Minnesota, USA
{"title":"Antithrombotic therapy in patients with COVID-19: indications, pharmacotherapy and controversy.","authors":"David Wang, Christopher Leo, Liping Liu, Li Huang, Lisa Huang, Yun Lu","doi":"10.1136/svn-2023-002321","DOIUrl":"10.1136/svn-2023-002321","url":null,"abstract":"Department of Neurology, Petznick Stroke Center, Barrow Neurological Institute, Phoenix, Arizona, USA Department of Medicine/ Division of General Internal Medicine/Hospital Medicine, Duke University, Durham, North Carolina, USA Neurosurgical Intensive Care Unit (NICU), Beijing Tiantan Hospital, Capital Medical University, Beijing, China China National Clinical Research Center for Neurological Diseases, Beijing, China Doctors Medical Center, Modesto, California, USA Chesapeake Regional Medical Center, Chesapeake, Virginia, USA Hennepin Healthcare System and the University of Minnesota, Minneapolis, Minnesota, USA","PeriodicalId":22021,"journal":{"name":"Stroke and Vascular Neurology","volume":"8 4","pages":"263-265"},"PeriodicalIF":5.9,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a9/70/svn-2023-002321.PMC10512043.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10195096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Homocysteine impedes neurite outgrowth recovery after intracerebral haemorrhage by downregulating pCAMK2A. 同型半胱氨酸通过下调pCAMK2A阻碍脑出血后神经突起生长的恢复。
IF 5.9 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2023-08-01 Epub Date: 2023-02-28 DOI: 10.1136/svn-2022-002165
Guangyu Guo, Jingfei Yang, Wenliang Guo, Hong Deng, Haihan Yu, Shuang Bai, Gaigai Li, Yingxin Tang, Ping Zhang, Yuming Xu, Chao Pan, Zhouping Tang

Hyperhomocysteinemia (HHcy) is independently associated with poorer long-term prognosis in patients with intracerebral haemorrhage (ICH); however, the effect and mechanisms of HHcy on ICH are still unclear. Here, we evaluated neurite outgrowth and neurological functional recovery using simulated models of ICH with HHcy in vitro and in vivo. We found that the neurite outgrowth velocity and motor functional recovery in the ICH plus HHcy group were significantly slower than that in the control group, indicating that homocysteine (Hcy) significantly impedes the neurite outgrowth recovery after ICH. Furthermore, phosphoproteomic data and signalome analysis of perihematomal brain tissues suggested that calmodulin-dependent protein kinases 2 (CAMK2A) kinase substrate pairs were significantly downregulated in ICH with HHcy compared with autologous blood injection only, both western blot and immunofluorescence staining confirmed this finding. Additionally, upregulation of pCAMK2A significantly increased neurite outgrowth recovery in ICH with HHcy. Collectively, we clarify the mechanism of HHcy-hindered neurite outgrowth recovery, and pCAMK2A may serve as a therapeutic strategy for promoting neurological recovery after ICH.

高同型半胱氨酸血症(HHcy)与脑出血(ICH)患者较差的长期预后独立相关;然而,HHcy对ICH的作用和机制尚不清楚。在这里,我们使用体外和体内具有HHcy的ICH模拟模型来评估轴突生长和神经功能恢复。我们发现ICH加HHcy组的轴突生长速度和运动功能恢复明显慢于对照组,表明同型半胱氨酸(Hcy)显著阻碍ICH后轴突生长恢复。此外,血周脑组织的磷酸蛋白质组学数据和信号组分析表明,与仅自体血液注射相比,在伴有HHcy的ICH中,钙调素依赖性蛋白激酶2(CAMK2A)激酶底物对显著下调,蛋白质印迹和免疫荧光染色均证实了这一发现。此外,pCAMK2A的上调显著增加了伴有HHcy的ICH中轴突生长的恢复。总之,我们阐明了HHcy阻碍轴突生长恢复的机制,pCAMK2A可能是促进脑出血后神经恢复的一种治疗策略。
{"title":"Homocysteine impedes neurite outgrowth recovery after intracerebral haemorrhage by downregulating pCAMK2A.","authors":"Guangyu Guo,&nbsp;Jingfei Yang,&nbsp;Wenliang Guo,&nbsp;Hong Deng,&nbsp;Haihan Yu,&nbsp;Shuang Bai,&nbsp;Gaigai Li,&nbsp;Yingxin Tang,&nbsp;Ping Zhang,&nbsp;Yuming Xu,&nbsp;Chao Pan,&nbsp;Zhouping Tang","doi":"10.1136/svn-2022-002165","DOIUrl":"10.1136/svn-2022-002165","url":null,"abstract":"<p><p>Hyperhomocysteinemia (HHcy) is independently associated with poorer long-term prognosis in patients with intracerebral haemorrhage (ICH); however, the effect and mechanisms of HHcy on ICH are still unclear. Here, we evaluated neurite outgrowth and neurological functional recovery using simulated models of ICH with HHcy in vitro and in vivo. We found that the neurite outgrowth velocity and motor functional recovery in the ICH plus HHcy group were significantly slower than that in the control group, indicating that homocysteine (Hcy) significantly impedes the neurite outgrowth recovery after ICH. Furthermore, phosphoproteomic data and signalome analysis of perihematomal brain tissues suggested that calmodulin-dependent protein kinases 2 (CAMK2A) kinase substrate pairs were significantly downregulated in ICH with HHcy compared with autologous blood injection only, both western blot and immunofluorescence staining confirmed this finding. Additionally, upregulation of pCAMK2A significantly increased neurite outgrowth recovery in ICH with HHcy. Collectively, we clarify the mechanism of HHcy-hindered neurite outgrowth recovery, and pCAMK2A may serve as a therapeutic strategy for promoting neurological recovery after ICH.</p>","PeriodicalId":22021,"journal":{"name":"Stroke and Vascular Neurology","volume":"8 4","pages":"335-348"},"PeriodicalIF":5.9,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6e/1e/svn-2022-002165.PMC10512087.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10206575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Arteriolosclerosis differs from venular collagenosis in relation to cerebrovascular parenchymal damages: an autopsy-based study. 动脉硬化症与小静脉胶原病在脑血管实质损伤方面的不同:一项基于尸检的研究。
IF 5.9 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2023-08-01 Epub Date: 2022-12-29 DOI: 10.1136/svn-2022-001924
Yuan Cao, Mei-Ying Huang, Chen-Hui Mao, Xue Wang, Yuan-Yuan Xu, Xiao-Jing Qian, Chao Ma, Wen-Ying Qiu, Yi-Cheng Zhu

Background and purpose: Cerebrovascular parenchymal damage is prevalent in ageing brains; however, its vascular aetiology has not been fully elucidated. In addition to the underlying role of sclerotic arterioles, the correlation between collagenised venules has not been clarified. Here, we aimed to investigate the associations between microvascular injuries, including arteriolosclerosis and venular collagenosis, and related parenchymal damages in ageing brains, to investigate the underlying correlations.

Methods: We evaluated arteriolosclerosis and venular collagenosis in 7 regions from 27 autopsy cases with no history of stroke or brain tumour. The correlations between the ratio of arteriolosclerosis, venular collagenosis and the severity of cerebrovascular parenchymal damage, including lacunes, microinfarcts, myelin loss, and parenchymal and perivascular haemosiderin deposits, were assessed.

Results: Arteriolosclerosis and venular collagenosis became more evident with age. Arteriolosclerosis was associated with lacunes (p=0.004) and brain parenchymal haemosiderin deposits in the superior frontal cortex (p=0.024) but not with leukoaraiosis severity. Venular collagenosis was not associated with the number of lacunes or haemosiderin, while white matter generally became paler with severe venular collagenosis in the periventricular (β=-0.430, p=0.028) and deep white matter (β=-0.437, p=0.025).

Conclusion: Our findings imply an important role for venular lesions in relation to microvessel-related parenchymal damage which is different from that for arteriolosclerosis. Different underlying mechanisms of both cerebral arterioles and venules require further investigation.

背景和目的:脑血管实质损伤在衰老的大脑中普遍存在;然而,其血管病因尚未完全阐明。除了硬化小动脉的潜在作用外,胶原化小静脉之间的相关性尚未阐明。在这里,我们旨在研究微血管损伤(包括动脉硬化和小静脉胶原病)与衰老大脑中相关实质损伤之间的关系,以研究潜在的相关性。方法:我们对27例无脑卒中或脑瘤病史的尸检病例中7个区域的动脉硬化和小静脉胶原病变进行了评估。评估了小动脉硬化、小静脉胶原病的比率与脑血管实质损伤的严重程度之间的相关性,包括出血、微出血、髓鞘丢失以及实质和血管周围的含铁血黄素沉积。结果:随着年龄的增长,动脉硬化症和小静脉胶原病变更加明显。动脉硬化症与上额叶皮质的血管(p=0.004)和脑实质含铁血黄素沉积有关(p=0.024),但与脑白质疏松症的严重程度无关。静脉胶原沉着症与系带或含铁血黄素的数量无关,而室周(β=0.430,p=0.028)和深部白质(β=0.437,p=0.025。脑小动脉和小静脉的不同潜在机制需要进一步研究。
{"title":"Arteriolosclerosis differs from venular collagenosis in relation to cerebrovascular parenchymal damages: an autopsy-based study.","authors":"Yuan Cao,&nbsp;Mei-Ying Huang,&nbsp;Chen-Hui Mao,&nbsp;Xue Wang,&nbsp;Yuan-Yuan Xu,&nbsp;Xiao-Jing Qian,&nbsp;Chao Ma,&nbsp;Wen-Ying Qiu,&nbsp;Yi-Cheng Zhu","doi":"10.1136/svn-2022-001924","DOIUrl":"10.1136/svn-2022-001924","url":null,"abstract":"<p><strong>Background and purpose: </strong>Cerebrovascular parenchymal damage is prevalent in ageing brains; however, its vascular aetiology has not been fully elucidated. In addition to the underlying role of sclerotic arterioles, the correlation between collagenised venules has not been clarified. Here, we aimed to investigate the associations between microvascular injuries, including arteriolosclerosis and venular collagenosis, and related parenchymal damages in ageing brains, to investigate the underlying correlations.</p><p><strong>Methods: </strong>We evaluated arteriolosclerosis and venular collagenosis in 7 regions from 27 autopsy cases with no history of stroke or brain tumour. The correlations between the ratio of arteriolosclerosis, venular collagenosis and the severity of cerebrovascular parenchymal damage, including lacunes, microinfarcts, myelin loss, and parenchymal and perivascular haemosiderin deposits, were assessed.</p><p><strong>Results: </strong>Arteriolosclerosis and venular collagenosis became more evident with age. Arteriolosclerosis was associated with lacunes (p=0.004) and brain parenchymal haemosiderin deposits in the superior frontal cortex (p=0.024) but not with leukoaraiosis severity. Venular collagenosis was not associated with the number of lacunes or haemosiderin, while white matter generally became paler with severe venular collagenosis in the periventricular (β=-0.430, p=0.028) and deep white matter (β=-0.437, p=0.025).</p><p><strong>Conclusion: </strong>Our findings imply an important role for venular lesions in relation to microvessel-related parenchymal damage which is different from that for arteriolosclerosis. Different underlying mechanisms of both cerebral arterioles and venules require further investigation.</p>","PeriodicalId":22021,"journal":{"name":"Stroke and Vascular Neurology","volume":"8 4","pages":"267-275"},"PeriodicalIF":5.9,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/02/eb/svn-2022-001924.PMC10512076.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10190319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Haemorrhage risk of brain arteriovenous malformation during pregnancy and puerperium. 妊娠期和产褥期脑动静脉畸形的出血风险。
IF 5.9 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2023-08-01 Epub Date: 2023-01-04 DOI: 10.1136/svn-2022-001921
Junyu Liu, Honghao Zhang, Chun Luo, Yuxin Guo, Yifeng Li, Dun Yuan, Weixi Jiang, Junxia Yan

Background: This study aimed to assess whether pregnancy and puerperium were associated with the risk of brain arteriovenous malformation (bAVM) haemorrhage.

Methods: A retrospective review was conducted in Xiangya Hospital, Central South University from January 2012 to December 2021. A case-crossover design was adopted to calculate the incidence density of bAVM-related haemorrhage among female patients in risk (pregnancy and puerperium) and control (non-pregnancy and non-puerperium) periods, according to four scenarios observed in different populations (scenario I: patients with haemorrhagic bAVM of all ages; scenario II: patients with haemorrhagic bAVM of all ages, with at least one previous pregnancy; scenario III: patients with haemorrhagic bAVM who are of reproductive age (15-45 years); scenario IV: patients with haemorrhagic bAVM of reproductive age (15-45 years), with at least one previous pregnancy. Next, a comprehensive literature aggregation (up to April 2022) was performed for evidence synthesis.

Results: Among the 311 female patients with haemorrhagic bAVM, a significant haemorrhage risk during pregnancy and puerperium was found in Scenarios I (relative risk [RR], 2.08; 95% CI, 1.28 to 3.39), II (RR, 3.21; 95% CI, 1.95 to 5.31) and IV (RR, 2.92; 95% CI, 1.73 to 4.93); however, a suggestive risk was found in scenario III (RR, 1.62; 95% CI, 0.99 to 2.67). Evidence synthesis revealed a consistent haemorrhage risk among patients of all ages (RR, 3.15; 95% CI, 1.93 to 5.15) and those of reproductive age (RR, 1.29; 95% CI, 0.89 to 1.86).

Conclusion: Compared with most previous studies, a higher but relatively moderate risk for bAVM-related haemorrhage was identified during pregnancy and puerperium. Individualised prevention and treatment strategies should be preferred when neurosurgeons make clinical decisions.

背景:本研究旨在评估妊娠和产褥期是否与脑动静脉畸形(bAVM)出血的风险相关。方法:对2012年1月至2021年12月在中南大学湘雅医院进行的回顾性分析。采用病例交叉设计计算高危期(妊娠期和产褥期)和对照期(非妊娠期和非产褥期,根据在不同人群中观察到的四种情况(情况I:所有年龄的出血性bAVM患者;情况II:所有年龄段的出血性b AVM患者,至少有一次妊娠;情况III:育龄(15-45岁)的出血性B AVM患者;场景IV:育龄(15-45岁)出血性bAVM患者,至少有一次妊娠史。接下来,进行了一次全面的文献汇总(截至2022年4月),以进行证据综合。结果:在311名出血性bAVM女性患者中,方案I(相对风险[RR],2.08;95%CI,1.28至3.39)、方案II(RR,3.21;95% CI,1.95至5.31)和IV(RR,2.92;95% CI为1.73至4.93);然而,在情景III中发现了提示性风险(RR,1.62;95% CI,0.99-2.67)。证据综合显示,所有年龄段的患者出血风险一致(RR,3.15;95% CI,1.93至5.15)和育龄人群(RR,1.29;95% CI,0.89-1.86)。结论:与大多数先前的研究相比,在妊娠和产褥期发现bAVM相关出血的风险更高但相对中等。神经外科医生在做出临床决策时,应首选个性化的预防和治疗策略。
{"title":"Haemorrhage risk of brain arteriovenous malformation during pregnancy and puerperium.","authors":"Junyu Liu,&nbsp;Honghao Zhang,&nbsp;Chun Luo,&nbsp;Yuxin Guo,&nbsp;Yifeng Li,&nbsp;Dun Yuan,&nbsp;Weixi Jiang,&nbsp;Junxia Yan","doi":"10.1136/svn-2022-001921","DOIUrl":"10.1136/svn-2022-001921","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to assess whether pregnancy and puerperium were associated with the risk of brain arteriovenous malformation (bAVM) haemorrhage.</p><p><strong>Methods: </strong>A retrospective review was conducted in Xiangya Hospital, Central South University from January 2012 to December 2021. A case-crossover design was adopted to calculate the incidence density of bAVM-related haemorrhage among female patients in risk (pregnancy and puerperium) and control (non-pregnancy and non-puerperium) periods, according to four scenarios observed in different populations (scenario I: patients with haemorrhagic bAVM of all ages; scenario II: patients with haemorrhagic bAVM of all ages, with at least one previous pregnancy; scenario III: patients with haemorrhagic bAVM who are of reproductive age (15-45 years); scenario IV: patients with haemorrhagic bAVM of reproductive age (15-45 years), with at least one previous pregnancy. Next, a comprehensive literature aggregation (up to April 2022) was performed for evidence synthesis.</p><p><strong>Results: </strong>Among the 311 female patients with haemorrhagic bAVM, a significant haemorrhage risk during pregnancy and puerperium was found in Scenarios I (relative risk [RR], 2.08; 95% CI, 1.28 to 3.39), II (RR, 3.21; 95% CI, 1.95 to 5.31) and IV (RR, 2.92; 95% CI, 1.73 to 4.93); however, a suggestive risk was found in scenario III (RR, 1.62; 95% CI, 0.99 to 2.67). Evidence synthesis revealed a consistent haemorrhage risk among patients of all ages (RR, 3.15; 95% CI, 1.93 to 5.15) and those of reproductive age (RR, 1.29; 95% CI, 0.89 to 1.86).</p><p><strong>Conclusion: </strong>Compared with most previous studies, a higher but relatively moderate risk for bAVM-related haemorrhage was identified during pregnancy and puerperium. Individualised prevention and treatment strategies should be preferred when neurosurgeons make clinical decisions.</p>","PeriodicalId":22021,"journal":{"name":"Stroke and Vascular Neurology","volume":"8 4","pages":"307-317"},"PeriodicalIF":5.9,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/56/db/svn-2022-001921.PMC10512072.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10206541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Roles of light transmission aggregometry and CYP2C19 genotype in predicting ischaemic complications during interventional therapy for intracranial aneurysms. 光透射聚集度测定和CYP2C19基因型在颅内动脉瘤介入治疗中预测缺血性并发症的作用。
IF 5.9 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2023-08-01 Epub Date: 2023-02-06 DOI: 10.1136/svn-2022-001720
Yangyang Zhou, Wenqiang Li, Chao Wang, Ruhang Xie, Yongnan Zhu, Qichen Peng, Limin Zhang, Hongqi Zhang, Yuxiang Gu, Shiqing Mu, Jian Liu, Xinjian Yang

Background and purpose: Light transmission aggregometry (LTA) and CYP2C19 genotype analysis are commonly used to evaluate the antiplatelet effects of clopidogrel during the interventional treatment of intracranial aneurysms. The aim of this study was to determine which test can predict ischaemic events during these treatments.

Methods: Patient demographic information, imaging data, laboratory data and ischaemic complications were recorded. LTA and CYP2C19 genotype results were compared, and multiple linear regression was performed to examine factors related to platelet reactivity. Multivariate regression analysis was performed to determine whether LTA and CYP2C19 could predict ischaemic complications and to identify other clinical risk factors. Receiver operating characteristic curve analysis was conducted to calculate the cut-off value for predicting ischaemic complications. A subgroup analysis was also performed for different CYP2C19 genotype metabolisers, as well as for patients with flow diverters and traditional stents.

Results: A total of 379 patients were included, of which 22 developed ischaemic events. Maximum platelet aggregation induced by ADP (ADP-MPA) could predict ischaemic events (p<0.001; area under the curve, 0.752 (95% CI 0.663 to 0.842)), and its cut-off value was 41.5%. ADP-MPA (p=0.001) and hypertension duration >10 years (p=0.022) were independent risk factors for ischaemic events, while the CYP2C19 genotype was not associated with ischaemic events. In the subgroup analysis, ADP-MPA could predict ischaemic events in fast metabolisers (p=0.004) and intermediate metabolisers (p=0.003). The cut-off value for ischaemic events was lower in patients with flow diverters (ADP-MPA=36.4%) than in patients with traditional stents (ADP-MPA=42.9%).

Conclusions: ADP-MPA can predict ischaemic complications during endovascular treatment of intracranial aneurysms. Patients with flow diverters require stronger antiplatelet medication than patients with traditional stents.

背景和目的:光透射聚集度测定法(LTA)和CYP2C19基因型分析通常用于评估氯吡格雷在颅内动脉瘤介入治疗中的抗血小板作用。本研究的目的是确定哪种测试可以预测这些治疗期间的缺血性事件。方法:记录患者的人口学信息、影像学数据、实验室数据和缺血性并发症。比较LTA和CYP2C19基因型结果,并进行多元线性回归以检查与血小板反应性相关的因素。进行多变量回归分析,以确定LTA和CYP2C19是否可以预测缺血性并发症,并确定其他临床风险因素。进行受试者操作特征曲线分析,以计算预测缺血性并发症的临界值。还对不同CYP2C19基因型代谢产物以及使用分流器和传统支架的患者进行了亚组分析。结果:共纳入379例患者,其中22例发生缺血性事件。ADP诱导的最大血小板聚集(ADP-MPA)可以预测缺血性事件(p10年(p=0.022)是缺血性事件的独立危险因素,而CYP2C19基因型与缺血性事件无关。在亚组分析中,ADP-MPA可预测快速代谢者(p=0.004)和中间代谢者(p=0.003。与使用传统支架的患者相比,使用分流器的患者需要更强的抗血小板药物。
{"title":"Roles of light transmission aggregometry and CYP2C19 genotype in predicting ischaemic complications during interventional therapy for intracranial aneurysms.","authors":"Yangyang Zhou,&nbsp;Wenqiang Li,&nbsp;Chao Wang,&nbsp;Ruhang Xie,&nbsp;Yongnan Zhu,&nbsp;Qichen Peng,&nbsp;Limin Zhang,&nbsp;Hongqi Zhang,&nbsp;Yuxiang Gu,&nbsp;Shiqing Mu,&nbsp;Jian Liu,&nbsp;Xinjian Yang","doi":"10.1136/svn-2022-001720","DOIUrl":"10.1136/svn-2022-001720","url":null,"abstract":"<p><strong>Background and purpose: </strong>Light transmission aggregometry (LTA) and CYP2C19 genotype analysis are commonly used to evaluate the antiplatelet effects of clopidogrel during the interventional treatment of intracranial aneurysms. The aim of this study was to determine which test can predict ischaemic events during these treatments.</p><p><strong>Methods: </strong>Patient demographic information, imaging data, laboratory data and ischaemic complications were recorded. LTA and CYP2C19 genotype results were compared, and multiple linear regression was performed to examine factors related to platelet reactivity. Multivariate regression analysis was performed to determine whether LTA and CYP2C19 could predict ischaemic complications and to identify other clinical risk factors. Receiver operating characteristic curve analysis was conducted to calculate the cut-off value for predicting ischaemic complications. A subgroup analysis was also performed for different CYP2C19 genotype metabolisers, as well as for patients with flow diverters and traditional stents.</p><p><strong>Results: </strong>A total of 379 patients were included, of which 22 developed ischaemic events. Maximum platelet aggregation induced by ADP (ADP-MPA) could predict ischaemic events (p<0.001; area under the curve, 0.752 (95% CI 0.663 to 0.842)), and its cut-off value was 41.5%. ADP-MPA (p=0.001) and hypertension duration >10 years (p=0.022) were independent risk factors for ischaemic events, while the CYP2C19 genotype was not associated with ischaemic events. In the subgroup analysis, ADP-MPA could predict ischaemic events in fast metabolisers (p=0.004) and intermediate metabolisers (p=0.003). The cut-off value for ischaemic events was lower in patients with flow diverters (ADP-MPA=36.4%) than in patients with traditional stents (ADP-MPA=42.9%).</p><p><strong>Conclusions: </strong>ADP-MPA can predict ischaemic complications during endovascular treatment of intracranial aneurysms. Patients with flow diverters require stronger antiplatelet medication than patients with traditional stents.</p>","PeriodicalId":22021,"journal":{"name":"Stroke and Vascular Neurology","volume":"8 4","pages":"327-334"},"PeriodicalIF":5.9,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f5/69/svn-2022-001720.PMC10512079.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10260876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Correction: Indobufen versus aspirin in acute ischaemic stroke (INSURE): rationale and design of a multicentre randomised trial. 更正:Indobufen与阿司匹林治疗急性缺血性中风(INSURE):一项多中心随机试验的原理和设计。
IF 5.9 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2023-08-01 Epub Date: 2023-02-21 DOI: 10.1136/svn-2021-001480corr1
{"title":"Correction: <i>Indobufen versus aspirin in acute ischaemic stroke (INSURE): rationale and design of a multicentre randomised trial</i>.","authors":"","doi":"10.1136/svn-2021-001480corr1","DOIUrl":"10.1136/svn-2021-001480corr1","url":null,"abstract":"","PeriodicalId":22021,"journal":{"name":"Stroke and Vascular Neurology","volume":"8 4","pages":"e2"},"PeriodicalIF":5.9,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7d/05/svn-2021-001480corr1.PMC10512067.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10060169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute right insular ischaemic lesions and poststroke left ventricular dysfunction. 急性右岛叶缺血性病变和卒中后左心室功能障碍。
IF 5.9 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2023-08-01 Epub Date: 2023-01-18 DOI: 10.1136/svn-2022-001724
Klemens Winder, Carolina Villegas Millar, Gabriela Siedler, Michael Knott, Arnd Dörfler, Anna Engel, Stephan Achenbach, Max J Hilz, Bernd Kallmünzer, Stefan Schwab, Frank Seifert, Kilian Fröhlich

Introduction: Myocardial injury related to acute ischaemic stroke is common even without primary cardiac disease. We intended to determine associations between values of left ventricular ejection fraction (LVEF) and ischaemic stroke lesion sites.

Methods: Of a local database, patients with acute first-ever ischaemic stroke confirmed by brain imaging but without pre-existing heart disease were included. The cardiac morphology and LVEF were obtained from transthoracic or transesophageal echocardiography, and impaired LVEF was categorised as mild (35%-50%), moderate (34%-25%) and severe (<25%). Patient age, stroke severity, ischaemic lesion volume, prevalence of troponin I increase (>0.1 ng/mL), atrial fibrillation and cardiac wall motion abnormalities were assessed and compared between patients with and without impaired LVEF after stroke (significance: p<0.05). A multivariate voxelwise lesion analysis correlated LVEF after stroke with sites of ischaemic lesions.

Results: Of 1209 patients who had a stroke, 231 (mean age 66.3±14.0 years) met the inclusion criteria; 40 patients (17.3%) had an impaired LVEF after stroke. Patients with impaired LVEF had higher infarct volumes (53.8 mL vs 30.0 mL, p=0.042), a higher prevalence of troponin increase (17.5% vs 4.2%, p=0.006), cardiac wall motion abnormalities (42.5% vs 5.2%, p<0.001) and atrial fibrillation (60.0% vs 26.2%, p<0.001) than patients with LVEF of >50%. The multivariate voxelwise lesion analysis yielded associations between decreased LVEF and damaged voxels in the insula, amygdala and operculum of the right hemisphere.

Conclusion: Our imaging analysis unveils a prominent role of the right hemispheric central autonomic network, especially of the insular cortex, in the brain-heart axis. Our results support preliminary evidence that acute ischaemic stroke in distinct brain regions of the central autonomic network may directly impair cardiac function and thus further supports the concept of a distinct stroke-heart syndrome.

引言:即使没有原发性心脏病,与急性缺血性中风相关的心肌损伤也很常见。我们旨在确定左心室射血分数(LVEF)值与缺血性卒中病变部位之间的相关性。方法:在一个本地数据库中,包括通过脑成像证实但没有预先存在心脏病的首次急性缺血性中风患者。通过经胸或经食道超声心动图获得心脏形态和LVEF,LVEF受损分为轻度(35%-50%)、中度(34%-25%)和重度(0.1 在卒中后LVEF受损和无LVEF受损的患者之间评估并比较心房颤动和心壁运动异常(显著性:p结果:在1209名卒中患者中,231名(平均年龄66.3±14.0岁)符合纳入标准;40名患者(17.3%)在卒中后LVEF受损。LVEF受损的患者梗死体积更大(53.8 mL与30.0 mL,p=0.042),肌钙蛋白增加的患病率较高(17.5%vs 4.2%,p=0.006),心壁运动异常(42.5%vs 5.2%,p50%。多变量体素病变分析显示,左心室射血分数下降与右半球岛叶、杏仁核和顶盖体素受损之间存在关联。结论:我们的影像学分析揭示了右半球中央自主神经网络,尤其是岛叶皮层在脑心轴中的重要作用。我们的结果支持初步证据中枢自主神经网络不同大脑区域的急性缺血性中风可能直接损害心脏功能,从而进一步支持不同中风-心脏综合征的概念。
{"title":"Acute right insular ischaemic lesions and poststroke left ventricular dysfunction.","authors":"Klemens Winder, Carolina Villegas Millar, Gabriela Siedler, Michael Knott, Arnd Dörfler, Anna Engel, Stephan Achenbach, Max J Hilz, Bernd Kallmünzer, Stefan Schwab, Frank Seifert, Kilian Fröhlich","doi":"10.1136/svn-2022-001724","DOIUrl":"10.1136/svn-2022-001724","url":null,"abstract":"<p><strong>Introduction: </strong>Myocardial injury related to acute ischaemic stroke is common even without primary cardiac disease. We intended to determine associations between values of left ventricular ejection fraction (LVEF) and ischaemic stroke lesion sites.</p><p><strong>Methods: </strong>Of a local database, patients with acute first-ever ischaemic stroke confirmed by brain imaging but without pre-existing heart disease were included. The cardiac morphology and LVEF were obtained from transthoracic or transesophageal echocardiography, and impaired LVEF was categorised as mild (35%-50%), moderate (34%-25%) and severe (<25%). Patient age, stroke severity, ischaemic lesion volume, prevalence of troponin I increase (>0.1 ng/mL), atrial fibrillation and cardiac wall motion abnormalities were assessed and compared between patients with and without impaired LVEF after stroke (significance: p<0.05). A multivariate voxelwise lesion analysis correlated LVEF after stroke with sites of ischaemic lesions.</p><p><strong>Results: </strong>Of 1209 patients who had a stroke, 231 (mean age 66.3±14.0 years) met the inclusion criteria; 40 patients (17.3%) had an impaired LVEF after stroke. Patients with impaired LVEF had higher infarct volumes (53.8 mL vs 30.0 mL, p=0.042), a higher prevalence of troponin increase (17.5% vs 4.2%, p=0.006), cardiac wall motion abnormalities (42.5% vs 5.2%, p<0.001) and atrial fibrillation (60.0% vs 26.2%, p<0.001) than patients with LVEF of >50%. The multivariate voxelwise lesion analysis yielded associations between decreased LVEF and damaged voxels in the insula, amygdala and operculum of the right hemisphere.</p><p><strong>Conclusion: </strong>Our imaging analysis unveils a prominent role of the right hemispheric central autonomic network, especially of the insular cortex, in the brain-heart axis. Our results support preliminary evidence that acute ischaemic stroke in distinct brain regions of the central autonomic network may directly impair cardiac function and thus further supports the concept of a distinct stroke-heart syndrome.</p>","PeriodicalId":22021,"journal":{"name":"Stroke and Vascular Neurology","volume":"8 4","pages":"301-306"},"PeriodicalIF":5.9,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/58/a4/svn-2022-001724.PMC10512080.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10260396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Angioarchitecture and prognosis of pediatric intracranial pial arteriovenous fistula. 儿童颅内软脑膜动静脉瘘的血管结构与预后。
IF 5.9 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2023-08-01 Epub Date: 2023-01-06 DOI: 10.1136/svn-2022-001979
Jingwei Li, Zhenlong Ji, Jiaxing Yu, Jian Ren, Fan Yang, Lisong Bian, Xinglong Zhi, Guilin Li, Hongqi Zhang

Objective: Pial arteriovenous fistulas (PAVFs) are rare and mostly observed in children. However, the overall angioarchitecture, clinical features, treatments and long-term prognosis for pediatric patients remain unclear.

Methods: Clinical data of consecutive 42 pediatric PAVFs were documented and analysed. According to the differences of age distribution and clinical features, they were split into a younger group (≤3 years old; 20 cases) and an older group (3-14 years old; 22 cases).

Results: Their mean age was 4.9±3.9 years, and the mean preoperative modified Rankin Scale (mRS) score was 1.64±1.57. Fourteen patients (33.3%) were asymptomatic, followed by epilepsy (21.4%), intracranial haemorrhage (16.7%), hydrocephalus (9.5%), developmental delay (7.1%), intermittent headache (7.1%) and congestive heart failure (4.8%). Annual bleeding rate and rebleeding rate before treatment reached 3.86% and 3.17%. Poor venous drainage including sinus dynamic obstruction (21 cases, 50.0%) and sinus occlusion (17 cases, 40.48%) were found with high frequency among these patients. Finally, 33 cases were cured (78.57%), and 4 cases faced surgery-related complications (9.52%). During 24-140 months' follow-up, the mean mRS score reduced to 0.57±0.40. However, only 22 cases (52.38%) recovered to absolutely normal, and poor venous drainage was the risk factor for patients' incomplete recovery (p=0.028, Exp(B)=14.692, 95% CI 1.346 to 160.392). Compared with the older group, younger group showed more chronic symptoms, more secondary pathological changes, more times treatment and worse prognosis (p=0.013, 0.002, 0.000 and 0.032, respectively).

Conclusions: Pediatric PAVF has different angioarchitectures, clinical features and prognoses in different age groups. Poor venous drainage is an important factor leading to poor prognosis, and it accounts for incomplete recovery in nearly half of patients.

目的:皮亚动静脉瘘(PAVFs)是一种罕见且多见于儿童的疾病。然而,儿科患者的总体血管结构、临床特征、治疗和长期预后仍不清楚。方法:对连续42例儿科PAVF的临床资料进行记录和分析。根据年龄分布和临床特征的差异,将他们分为年轻组(≤3岁;20例)和老年组(3-14岁;22例)。结果:他们的平均年龄为4.9±3.9岁,术前改良兰金量表(mRS)的平均得分为1.64±1.57。14例(33.3%)无症状,其次是癫痫(21.4%)、颅内出血(16.7%)、脑积水(9.5%)、发育迟缓(7.1%),间歇性头痛(7.1%)和充血性心力衰竭(4.8%)。年出血率和治疗前再出血率分别达到3.86%和3.17%。静脉引流不良,包括窦性动力性梗阻(21例,50.0%)和窦性闭塞(17例,40.48%)。最终,33例(78.57%)治愈,4例(9.52%)面临手术相关并发症。在24-140个月的随访中,平均mRS评分降至0.57±0.40。然而,只有22例(52.38%)恢复到绝对正常,静脉引流不良是患者不完全恢复的危险因素(p=0.028,Exp(B)=14.692,95%CI 1.346至160.392),治疗次数多,预后差(分别为p=0.013、0.002、0.000和0.032)。结论:不同年龄组的儿童PAFF具有不同的血管结构、临床特征和预后。静脉引流不良是导致预后不良的一个重要因素,它导致了近一半患者的不完全康复。
{"title":"Angioarchitecture and prognosis of pediatric intracranial pial arteriovenous fistula.","authors":"Jingwei Li,&nbsp;Zhenlong Ji,&nbsp;Jiaxing Yu,&nbsp;Jian Ren,&nbsp;Fan Yang,&nbsp;Lisong Bian,&nbsp;Xinglong Zhi,&nbsp;Guilin Li,&nbsp;Hongqi Zhang","doi":"10.1136/svn-2022-001979","DOIUrl":"10.1136/svn-2022-001979","url":null,"abstract":"<p><strong>Objective: </strong>Pial arteriovenous fistulas (PAVFs) are rare and mostly observed in children. However, the overall angioarchitecture, clinical features, treatments and long-term prognosis for pediatric patients remain unclear.</p><p><strong>Methods: </strong>Clinical data of consecutive 42 pediatric PAVFs were documented and analysed. According to the differences of age distribution and clinical features, they were split into a younger group (≤3 years old; 20 cases) and an older group (3-14 years old; 22 cases).</p><p><strong>Results: </strong>Their mean age was 4.9±3.9 years, and the mean preoperative modified Rankin Scale (mRS) score was 1.64±1.57. Fourteen patients (33.3%) were asymptomatic, followed by epilepsy (21.4%), intracranial haemorrhage (16.7%), hydrocephalus (9.5%), developmental delay (7.1%), intermittent headache (7.1%) and congestive heart failure (4.8%). Annual bleeding rate and rebleeding rate before treatment reached 3.86% and 3.17%. Poor venous drainage including sinus dynamic obstruction (21 cases, 50.0%) and sinus occlusion (17 cases, 40.48%) were found with high frequency among these patients. Finally, 33 cases were cured (78.57%), and 4 cases faced surgery-related complications (9.52%). During 24-140 months' follow-up, the mean mRS score reduced to 0.57±0.40. However, only 22 cases (52.38%) recovered to absolutely normal, and poor venous drainage was the risk factor for patients' incomplete recovery (p=0.028, Exp(B)=14.692, 95% CI 1.346 to 160.392). Compared with the older group, younger group showed more chronic symptoms, more secondary pathological changes, more times treatment and worse prognosis (p=0.013, 0.002, 0.000 and 0.032, respectively).</p><p><strong>Conclusions: </strong>Pediatric PAVF has different angioarchitectures, clinical features and prognoses in different age groups. Poor venous drainage is an important factor leading to poor prognosis, and it accounts for incomplete recovery in nearly half of patients.</p>","PeriodicalId":22021,"journal":{"name":"Stroke and Vascular Neurology","volume":"8 4","pages":"292-300"},"PeriodicalIF":5.9,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/03/fd/svn-2022-001979.PMC10512084.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10196528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rationale and design of a randomised double-blind 2×2 factorial trial comparing the effect of a 3-month intensive statin and antiplatelet therapy for patients with acute mild ischaemic stroke or high-risk TIA with intracranial or extracranial atherosclerosis (INSPIRES). 一项随机双盲 2×2 因式试验(INSPIRES)的原理和设计,该试验比较了对急性轻度缺血性脑卒中或高危 TIA 且伴有颅内或颅外动脉粥样硬化的患者进行为期 3 个月的他汀类药物强化治疗和抗血小板治疗的效果。
IF 5.9 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2023-06-01 Epub Date: 2023-01-27 DOI: 10.1136/svn-2022-002084
Ying Gao, Yuesong Pan, Shangrong Han, Weiqi Chen, Jing Jing, Chunjuan Wang, Yingying Yang, Tingting Wang, Xia Meng, Xingquan Zhao, Liping Liu, Hao Li, S Claiborne Johnston, Pierre Amarenco, Philip M Bath, Yongjun Wang, Yilong Wang

Background: It remains unclear if intensive antiplatelet and statin treatments begun within 24-72 hours of cerebral ischaemic events from intracranial or extracranial atherosclerosis is effective or safe.

Methods: The Intensive Statin and Antiplatelet Therapy for High-risk Intracranial or Extracranial Atherosclerosis (INSPIRES) trial is a randomised, double-blind, placebo-controlled, multicentre and 2×2 factorial trial. 6100 individuals between the ages of 35 and 80 who have experienced a mild ischaemic stroke or high-risk transient ischaemic attack (TIA) within the previous 72 hours that is attributed to ≥50% atherosclerotic stenosis of a major intracranial or extracranial artery or multiple infarctions of atherosclerotic origin will be enrolled in the trial. Eligible subjects will be randomised 1:1:1:1 to one of four groups: (1) intensive antiplatelet therapy (combined clopidogrel and aspirin for days 1-21, then aspirin placebo and clopidogrel for days 22-90) plus immediate intensive statin therapy(atorvastatin at a dose of 80 mg daily for the first 21 days, then 40 mg daily for days 22-90); (2) intensive antiplatelet therapy plus delayed intensive statin therapy (atorvastatin placebo for days 1-3, followed by 40 mg per day of atorvastatin for days 4-90); (3) standard antiplatelet therapy (combination of clopidogrel placebo with aspirin for 90 days) plus immediate intensive statin therapy and (4) standard antiplatelet therapy plus delayed intensive statin therapy. The primary efficacy endpoint is any new stroke (ischaemic or haemorrhagic) within 90 days after randomisation. The primary safety endpoint is moderate to severe bleeding at 90 days.

Conclusion: The INSPIRES trial will assess the efficacy and safety of intensive antiplatelet therapy and immediate intensive statin therapy begun within 72 hours of onset in decreasing the recurrent stroke at 90 days in patients with acute mild ischaemic stroke or high-risk TIA of intracranial or extracranial atherosclerosis origin.

Trial registration number: NCT03635749.

背景:在颅内或颅外动脉粥样硬化导致脑缺血事件发生后 24-72 小时内开始强化抗血小板和他汀类药物治疗是否有效或安全,目前仍不清楚:高危颅内或颅外动脉粥样硬化的他汀类药物和抗血小板强化治疗(INSPIRES)试验是一项随机、双盲、安慰剂对照、多中心、2×2因子试验。试验将招募 6100 名年龄在 35 岁至 80 岁之间、在 72 小时内发生过轻度缺血性中风或高危短暂性脑缺血发作 (TIA)、颅内或颅外大动脉动脉粥样硬化性狭窄≥50% 或动脉粥样硬化性多发性脑梗塞的患者。符合条件的受试者将以 1:1:1:1 的比例被随机分配到四组中的一组:(1) 强化抗血小板疗法(第 1-21 天联合使用氯吡格雷和阿司匹林,第 22-90 天使用阿司匹林安慰剂和氯吡格雷)加立即强化他汀疗法(前 21 天每天服用 80 毫克阿托伐他汀,第 22-90 天每天服用 40 毫克阿托伐他汀);(2) 强化抗血小板疗法加延迟强化他汀疗法(第 1-3 天服用阿托伐他汀安慰剂,第 4-90 天每天服用 40 毫克阿托伐他汀);(3) 标准抗血小板疗法(氯吡格雷安慰剂与阿司匹林联合用药 90 天)加立即强化他汀疗法,以及 (4) 标准抗血小板疗法加延迟强化他汀疗法。主要疗效终点是随机分组后 90 天内的任何新中风(缺血性或出血性)。主要安全性终点为 90 天内中度至重度出血:INSPIRES试验将评估急性轻度缺血性脑卒中或颅内、外动脉粥样硬化引起的高危TIA患者在发病72小时内开始强化抗血小板治疗和立即强化他汀类药物治疗对减少90天内脑卒中复发的有效性和安全性:试验注册号:NCT03635749。
{"title":"Rationale and design of a randomised double-blind 2×2 factorial trial comparing the effect of a 3-month intensive statin and antiplatelet therapy for patients with acute mild ischaemic stroke or high-risk TIA with intracranial or extracranial atherosclerosis (INSPIRES).","authors":"Ying Gao, Yuesong Pan, Shangrong Han, Weiqi Chen, Jing Jing, Chunjuan Wang, Yingying Yang, Tingting Wang, Xia Meng, Xingquan Zhao, Liping Liu, Hao Li, S Claiborne Johnston, Pierre Amarenco, Philip M Bath, Yongjun Wang, Yilong Wang","doi":"10.1136/svn-2022-002084","DOIUrl":"10.1136/svn-2022-002084","url":null,"abstract":"<p><strong>Background: </strong>It remains unclear if intensive antiplatelet and statin treatments begun within 24-72 hours of cerebral ischaemic events from intracranial or extracranial atherosclerosis is effective or safe.</p><p><strong>Methods: </strong>The Intensive Statin and Antiplatelet Therapy for High-risk Intracranial or Extracranial Atherosclerosis (INSPIRES) trial is a randomised, double-blind, placebo-controlled, multicentre and 2×2 factorial trial. 6100 individuals between the ages of 35 and 80 who have experienced a mild ischaemic stroke or high-risk transient ischaemic attack (TIA) within the previous 72 hours that is attributed to ≥50% atherosclerotic stenosis of a major intracranial or extracranial artery or multiple infarctions of atherosclerotic origin will be enrolled in the trial. Eligible subjects will be randomised 1:1:1:1 to one of four groups: (1) intensive antiplatelet therapy (combined clopidogrel and aspirin for days 1-21, then aspirin placebo and clopidogrel for days 22-90) plus immediate intensive statin therapy(atorvastatin at a dose of 80 mg daily for the first 21 days, then 40 mg daily for days 22-90); (2) intensive antiplatelet therapy plus delayed intensive statin therapy (atorvastatin placebo for days 1-3, followed by 40 mg per day of atorvastatin for days 4-90); (3) standard antiplatelet therapy (combination of clopidogrel placebo with aspirin for 90 days) plus immediate intensive statin therapy and (4) standard antiplatelet therapy plus delayed intensive statin therapy. The primary efficacy endpoint is any new stroke (ischaemic or haemorrhagic) within 90 days after randomisation. The primary safety endpoint is moderate to severe bleeding at 90 days.</p><p><strong>Conclusion: </strong>The INSPIRES trial will assess the efficacy and safety of intensive antiplatelet therapy and immediate intensive statin therapy begun within 72 hours of onset in decreasing the recurrent stroke at 90 days in patients with acute mild ischaemic stroke or high-risk TIA of intracranial or extracranial atherosclerosis origin.</p><p><strong>Trial registration number: </strong>NCT03635749.</p>","PeriodicalId":22021,"journal":{"name":"Stroke and Vascular Neurology","volume":"8 3","pages":"249-258"},"PeriodicalIF":5.9,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c1/0d/svn-2022-002084.PMC10359782.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9905921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence and risk factors of stroke in China: a national serial cross-sectional study from 2003 to 2018. 中国脑卒中患病率及危险因素:2003 - 2018年全国系列横断面研究
IF 5.9 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2023-06-01 DOI: 10.1136/svn-2022-001598
Dai-Shi Tian, Chen-Chen Liu, Chao-Long Wang, Chuan Qin, Ming-Huan Wang, Wen-Hua Liu, Jian Liu, Han-Wen Zhang, Rong-Guo Zhang, Shao-Kang Wang, Xiao-Xiang Zhang, Liang Wang, Deng-Ji Pan, Jian-Ping Hu, Xiang Luo, Sha-Bei Xu, Wei Wang

Stroke imposes a substantial burden worldwide. With the rapid economic and lifestyle transition in China, trends of the prevalence of stroke across different geographic regions in China remain largely unknown. Capitalizing on the data in the National Health Services Surveys (NHSS), we assessed the prevalence and risk factors of stroke in China from 2003 to 2018. In this study, data from 2003, 2008, 2013, and 2018 NHSS were collected. Stroke cases were based on participants' self-report of a previous diagnosis by clinicians. We estimated the trends of stroke prevalence for the overall population and subgroups by age, sex, and socioeconomic factors, then compared across different geographic regions. We applied multivariable logistic regression to assess associations between stroke and risk factors. The number of participants aged 15 years or older were 154,077, 146,231, 230,067, and 212,318 in 2003, 2008, 2013, and 2018, respectively, among whom, 1435, 1996, 3781, and 6069 were stroke patients. The age and sex standardized prevalence per 100,000 individuals was 879 in 2003, 1100 in 2008, 1098 in 2013, and 1613 in 2018. Prevalence per 100,000 individuals in rural areas increased from 669 in 2003 to 1898 in 2018, while urban areas had a stable trend from 1261 in 2003 to 1365 in 2018. Across geographic regions, the central region consistently had the highest prevalence, but the western region has an alarmingly increasing trend from 623/100,000 in 2003 to 1898/100,000 in 2018 (P trend<0.001), surpassing the eastern region in 2013. Advanced age, male sex, rural area, central region, hypertension, diabetes, depression, low education and income level, retirement or unemployment, excessive physical activity, and unimproved sanitation facilities were significantly associated with stroke. In conclusion, the increasing prevalence of stroke in China was primarily driven by economically underdeveloped regions. It is important to develop targeted prevention programs in underdeveloped regions. Besides traditional risk factors, more attention should be paid to nontraditional risk factors to improve the prevention of stroke.

中风在全世界造成了巨大的负担。随着中国经济和生活方式的快速转变,中国不同地理区域中风患病率的趋势在很大程度上仍然未知。利用国家卫生服务调查(NHSS)的数据,我们评估了2003年至2018年中国中风的患病率和危险因素。在这项研究中,收集了2003年、2008年、2013年和2018年NHSS的数据。中风病例是基于参与者对先前临床医生诊断的自我报告。我们根据年龄、性别和社会经济因素估计了总体人群和亚组中风患病率的趋势,然后在不同地理区域进行比较。我们应用多变量逻辑回归来评估卒中与危险因素之间的关系。2003年、2008年、2013年和2018年,年龄在15岁及以上的受试者人数分别为154,077、146,231、230,067和212,318人,其中卒中患者人数分别为1435人、1996人、3781人和6069人。2003年每10万人中年龄和性别标准化患病率为879,2008年为1100,2013年为1098,2018年为1613。农村地区每10万人的患病率从2003年的669例上升到2018年的1898例,城市地区从2003年的1261例上升到2018年的1365例,呈稳定趋势。从地理区域来看,中部地区的患病率始终最高,但西部地区的患病率从2003年的623/10万上升到2018年的1898/10万(P趋势)
{"title":"Prevalence and risk factors of stroke in China: a national serial cross-sectional study from 2003 to 2018.","authors":"Dai-Shi Tian,&nbsp;Chen-Chen Liu,&nbsp;Chao-Long Wang,&nbsp;Chuan Qin,&nbsp;Ming-Huan Wang,&nbsp;Wen-Hua Liu,&nbsp;Jian Liu,&nbsp;Han-Wen Zhang,&nbsp;Rong-Guo Zhang,&nbsp;Shao-Kang Wang,&nbsp;Xiao-Xiang Zhang,&nbsp;Liang Wang,&nbsp;Deng-Ji Pan,&nbsp;Jian-Ping Hu,&nbsp;Xiang Luo,&nbsp;Sha-Bei Xu,&nbsp;Wei Wang","doi":"10.1136/svn-2022-001598","DOIUrl":"https://doi.org/10.1136/svn-2022-001598","url":null,"abstract":"<p><p>Stroke imposes a substantial burden worldwide. With the rapid economic and lifestyle transition in China, trends of the prevalence of stroke across different geographic regions in China remain largely unknown. Capitalizing on the data in the National Health Services Surveys (NHSS), we assessed the prevalence and risk factors of stroke in China from 2003 to 2018. In this study, data from 2003, 2008, 2013, and 2018 NHSS were collected. Stroke cases were based on participants' self-report of a previous diagnosis by clinicians. We estimated the trends of stroke prevalence for the overall population and subgroups by age, sex, and socioeconomic factors, then compared across different geographic regions. We applied multivariable logistic regression to assess associations between stroke and risk factors. The number of participants aged 15 years or older were 154,077, 146,231, 230,067, and 212,318 in 2003, 2008, 2013, and 2018, respectively, among whom, 1435, 1996, 3781, and 6069 were stroke patients. The age and sex standardized prevalence per 100,000 individuals was 879 in 2003, 1100 in 2008, 1098 in 2013, and 1613 in 2018. Prevalence per 100,000 individuals in rural areas increased from 669 in 2003 to 1898 in 2018, while urban areas had a stable trend from 1261 in 2003 to 1365 in 2018. Across geographic regions, the central region consistently had the highest prevalence, but the western region has an alarmingly increasing trend from 623/100,000 in 2003 to 1898/100,000 in 2018 (<i>P</i> <sub>trend</sub><0.001), surpassing the eastern region in 2013. Advanced age, male sex, rural area, central region, hypertension, diabetes, depression, low education and income level, retirement or unemployment, excessive physical activity, and unimproved sanitation facilities were significantly associated with stroke. In conclusion, the increasing prevalence of stroke in China was primarily driven by economically underdeveloped regions. It is important to develop targeted prevention programs in underdeveloped regions. Besides traditional risk factors, more attention should be paid to nontraditional risk factors to improve the prevention of stroke.</p>","PeriodicalId":22021,"journal":{"name":"Stroke and Vascular Neurology","volume":"8 3","pages":"238-248"},"PeriodicalIF":5.9,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/be/17/svn-2022-001598.PMC10359805.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10032880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
期刊
Stroke and Vascular Neurology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1